Ipsen Pharma - CEO of Ipsen Pharma
David Loew was appointed as
Chief Executive Officer of Ipsen on
July 1, 2020.
David brings nearly 30 years of leadership and experience across a range of therapeutic areas, including oncology, CNS and cardio-metabolism, as well as consumer healthcare. He has worked in the U.S., European and international markets. He began his career at Coopers & Lybrand and Hewlett Packard in 1990 before joining Roche in 1992. Over the following two decades, David held a variety of positions, including Global Oncology Head, Global Chief Marketing Officer & Head of Global Product Strategy and Region Head, Eastern Europe, Middle East and Africa for the Pharma Division of Roche. He joined Sanofi in July 2013 as Senior Vice President, Commercial Operations Europe, where he was responsible for the prescription, consumer healthcare and generics business across the EU region. In 2016, David was appointed CEO of Sanofi Pasteur Vaccines.
David currently serves on the Boards of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and G5 Santé, the federation of French pharmaceutical companies.
David earned his BA in Business Administration and MBA from the University of St. Gallen, Switzerland.
At Ipsen, we’re dedicated to improving people’s lives and health outcomes. Our 4,500 employees around the world are committed to tackling areas of high unmet medical need to improve the quality of life of patients and caregivers.
Ipsen’s vision is to be a leading global mid-size biopharmaceutical company, with a focus on transformative medicines in three key therapeutic areas: oncology, rare disease and neuroscience.
Under the overarching theme of Focus. Together. For patients & society, Ipsen is focusing on four strategic priorities to accelerate our innovation and drive positive impact for patients, employees, shareholders and society—a strategy for the short and long term.
We are working to maximize the value of our core products. Our objective is to take patient-centricity to the next level by truly impacting medical care and patient outcomes in our therapeutic areas, notably by building a deep understanding of the patient journey. Patient insights are essential to challenge the status quo, while collaboration with healthcare systems can bring about advancements for patients around the world.
The most promising assets in our portfolio are accelerated and prioritized. We are also executing an ambitious and focused external innovation and business development plan to add important new assets to our existing portfolio, with a cumulative firepower of €3 billion over the next four years. We are expanding the scope of our external innovation efforts across all stages of development, including late and early stage deals.
Efficiencies are a key part of our financial outlook for 2024 and will support growth with three objectives: invest in the growth of established products; support the launch of new medicines or new indications; and fuel external innovation.
Attracting, developing and retaining highly engaged talent is essential, by building on our employees’ strong engagement and supporting their professional development. We nurture a culture of focus and high performance by increasing accountability for faster and better decision-making. In addition, we want to broaden and deepen our expertise as well as fully leverage the collective intelligence of the company. We are accelerating our efforts to truly embrace diversity in all our facets and make Ipsen a more inclusive organization. Our commitment extends to the well-being of all employees, patients, healthcare systems and communities.